Response and Acquired Resistance to Everolimus in Anaplastic Thyroid Cancer

Response and Acquired Resistance to Everolimus in Anaplastic Thyroid Cancer

Everolimus, an inhibitor of the mammalian target of rapamycin (mTOR), is effective in treating tumors harboring alterations in the mTOR pathway. Mechanisms of resistance to everolimus remain undefined. Resistance developed in a patient with metastatic anaplastic thyroid carcinoma after an extraordin...

Full description

Bibliographic Details
Main Authors: Van Allen, Eliezer M. (Author), Amin-Mansour, Ali (Author), Taylor-Weiner, Amaro (Author), Rosenberg, Mara (Author), Barletta, Justine A. (Author), Guo, Yanan (Author), Swanson, Scott J. (Author), Ruan, Daniel T. (Author), Hanna, Glenn J. (Author), Haddad, Robert I. (Author), Kwiatkowski, David J. (Author), Jänne, Pasi A. (Author), Lorch, Jochen H. (Author), Wagle, Nikhil (Contributor), Grabiner, Brian (Contributor), Gray, Nathanael S (Contributor), Getz, Gad Asher (Contributor), Carter, Scott (Contributor), Sabatini, David (Contributor), Garraway, Levi A. (Author)
Other Authors: Massachusetts Institute of Technology. Institute for Medical Engineering & Science (Contributor), Broad Institute of MIT and Harvard (Contributor), Massachusetts Institute of Technology. Department of Biology (Contributor), Garraway, Levi (Contributor)
Format: Article
Language:English
Published: New England Journal of Medicine, 2017-04-21T19:26:46Z.
Subjects:
Article
Online Access:Get fulltext

Similar Items

Similar Items